Dipexium Pharmaceuticals, Inc. (DPRX) Shares Tumble on Disappointing Locilex® Phase 3 Studies
Shares of Dipexium Pharmaceuticals (NASDAQ: DPRX) plummeted more than 80% after the company reported that OneStep phase 3 clinical trials of its lead candidate Locilex® failed to meet primary or secondary endpoints in the treatment of mild infections of diabetic foot ulcers. "Although we are disappointed with these results, we are continuing to evaluate the data and will consider potential regulatory pathways forward in other possible clinical indications based on an evaluation of all data emerging from the phase 3 studies,” David P. Luci, president and CEO of Dipexium, stated in the news release. To view the full press release,…